Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Apr 30 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced that it received final approval from the USFDA for Niacin Extended-Release Tablets in various strengths. These tablets are indicated for managing cholesterol levels and reducing the risk of myocardial infarction in certain patients. The manufacturing will take place at Zydus's facility in Moraiya, Ahmedabad.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 30, 2025, titled "Zydus receives final approval from USFDA for Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases